Feb 26, 2026 4:01 pm EST Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
Feb 19, 2026 4:01 pm EST Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026
Jan 20, 2026 7:00 am EST Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care
Jan 13, 2026 7:00 am EST Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026
Jan 12, 2026 7:00 am EST MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026